Ascletis announces poster presentations on the study results of asc30 and asc47 at the 85th scientific sessions of american diabetes association (ada)

Hong kong , june 8, 2025 /prnewswire/ -- ascletis pharma inc. (hkex: 1672, "ascletis") announces that poster presentations on preliminary studies of its oral small molecule glp-1 receptor (glp-1r) agonist asc30 and adipose-targeted, muscle-preserving weight loss drug candidate asc47 will be presented at the 85th scientific sessions of american diabetes association (ada) in chicago, u.s. details of the poster presentations poster number: 750-p abstract title: asc30, an oral glp-1r biased small molecule agonist in participants with obesity—a first-in-human single ascending dose study session type: general poster session location: poster hall (hall f1) presentation time: sunday jun 22, 2025 12:30 pm - 1:30 pm (chicago time), i.e., monday jun 23, 2025 1:30 am - 2:30 am (beijing time) poster number: 847-p abstract title: asc47, a muscle-preserving weight loss drug candidate for obesity, in combination with semaglutide, demonstrated superior weight loss to semaglutide monotherapy in a preclinical model session type: general poster session location: poster hall (hall f1) presentation time: sunday jun 22, 2025 12:30 pm - 1:30 pm (chicago time), i.e.
ASC Ratings Summary
ASC Quant Ranking